KRAS p.G13D mutation and codon 12 mutations are not created equal in predicting clinical outcomes of cetuximab in metastatic colorectal cancer: a systematic review and meta-analysis.

摘要: BACKGROUND: The authors conducted a systematic review and meta-analysis to examine whether patients who had metastatic colorectal cancer (mCRC) with the v-Ki-ras2 Kirsten rat sarcoma viral oncogene homolog (KRAS) p.G13D mutation (an amino acid substitution at position 13 in KRAS from glycine an aspartic acid) received cetuximab treatment better clinical outcomes than mCRC tumors codon 12 mutations. METHODS: Relevant studies were identified by search of MEDLINE, EMBASE, Chinese Biomedical Database, Wan Fang Digital Journals inception October 2011. The primary included objective response rate (ORR), progression-free survival (PFS), overall (OS). pooled relative risk (RR) or hazard ratio (HR) was estimated using fixed-effects random-effects models according heterogeneity between studies. RESULTS: Ten considered eligible that 1487 mCRC. Patients significantly higher ORR (10 studies; RR, 1.642; 95% confidence interval [CI], 1.131-2.384), longer PFS (1 study; HR, 0.54; CI, 0.36-0.81), OS 0.52; 0.33-0.80) mutations. Compared wild-type tumors, lower (9 0.540; 0.381-0.765) nonsignificantly shorter 0.99; 0.68-1.45) 1.01; 0.66-1.54). CONCLUSIONS: Patients appeared benefit more However, because limited sample sizes current meta-analysis, these results should be interpreted caution. Cancer 2013. © 2012 American Society.